Second dose of the Pfizer/BioNTech vaccine boosts antibody increase

Instituto Gulbenkian de Ciência and Centro Hospitalar Lisboa Ocidental, E.P.E. have been collaborating on SARS-CoV-2 virus surveillance projects in healthcare workers. The results of the second phase of the SARS-CoV-2 vaccine effectiveness study reveal that 99.8% of the healthcare workers at CHLO developed significant antibodies after taking the second dose of the vaccine.

The data also shows an insignificant increase in antibodies at the mucosa level, the main source of contamination and transmission of the disease. Results lead to recommend not to increase the interval between doses and to maintain individual protection care even after the vaccination process.

Check the latest news in the press about this study (in Portuguese):

in RTP

in Expresso

in SIC Notícias

in TSF

in Sábado

in Diário de Notícias

in Jornal de Notícias

in TVI 24